お見積

サンプルお申込み

お問い合わせ

今すぐ購入

※ご注文方法：お問い合わせフォームまたはメールにてご連絡ください。
支払方法：「銀行振込」の場合， 注文の確認後、ご指定のメールアドレスに電子版の請求書をお送りいたしますので、電子版の請求書の記載事項に従って送金操作を行ってください。
※納期：原則として、受注後2～4営業日以内に発送いたします。 但し、日本語版が必要な場合は、受注後8～10営業日となります。 お客様のニーズに合わせて、事前にご注文のスケジュールをお立てください。

本報告書は、腫瘍薬の世界市場、容量、生産量、収益、価格の概要を紹介します。2020~2024年の歴史的な市場収益/売上データ、2025年の予想、および2031年までのCAGRの予測を含む世界市場動向の分析。本レポートはメーカー、地域、製品の種類と端末業界の角度から世界と主要地域の市場現状と将来性を研究した、このレポートでは、世界と主要地域のトップメーカーを分析し、製品タイプとアプリケーション/端末業界別に腫瘍薬市場を分類しています。
本レポートでは世界の腫瘍薬市場の主な参加者として、企業概要、販売数量、収益、価格、粗利益率、ポートフォリオ、地理的位置、重要な発展を次のパラメータに基づいて紹介します。本研究に含まれる主な企業は：Roche、Celgene、Novartis、Bristol-Myers Squibb、Johnson & Johnson、Merck & Co.、AstraZeneca、Pfizer、Amgen、Eli Lilly、AbbVie、Takeda、Astellas、Ipsen、Sanofi、Bayer、Biogen Idec、Teva、Otsuka、Eisai、Merck KGaA、Gilead Sciences、Hengrui Medicine

レポートは腫瘍薬の主要生産者を調査し、主要地域や国の消費状況も提供します。腫瘍薬の今後の市場の可能性のハイライト、およびこの市場をさまざまなセグメントおよびサブセグメントに予測するための主要な地域/国の焦点。アメリカとカナダ、中国、アジア、ヨーロッパ、中東、アフリカ、ラテンアメリカ、およびその他の国の国別データと市場価値分析。

2020年から2031年までのタイプ別および用途別、売上高、収益、価格別のセグメントデータを分析します。
タイプ別市場セグメント：
    Chemotherapy
    Targeted Therapy
    Immunotherapy (Biologic Therapy)
    Hormonal Therapy
    Others

用途別の市場セグメント：
    Blood Cancer
    Breast Cancer
    Gastrointestinal Cancer
    Prostate Cancer
    Respiratory or Lung Cancer
    Others

本レポートの詳細内容
本レポートは、世界の腫瘍薬市場の現状と将来展望を包括的に分析し、グローバルの主要地域における開発動向の綿密な調査を通じて、読者に包括的な市場分析を提示するものであります。市場の全体像を把握するために、プレイヤー、地域、製品タイプ、最終産業を網羅した多角的な分析を提供しています。さらに、世界市場のトッププレイヤーを特定し、プロファイルを作成するとともに、製品タイプや用途/最終産業に基づいて腫瘍薬市場を細分化しています。この分類と応用により、市場の構造とダイナミクスをより深く理解することができ、情報に基づいた意思決定と戦略立案が可能になります。
一. 生産面では、2020年から2025年まで、そして2031年までの予測として、メーカー別、地域別（地域レベル、国レベル）の腫瘍薬生産量、成長率、市場シェアを調査している。

二. 消費面では、腫瘍薬の売上高を地域別（地域レベル・国レベル）、企業別、種類別、用途別に焦点を当てています。2020年から2025年まで、2031年までの予測。

三.主要メーカーの腫瘍薬売上高、収益、市場シェア、業界ランキング、2020年から2025年までのデータに焦点を当てています。世界の腫瘍薬市場における主要なステークホルダーの特定、最近の動向とセグメント収益に基づいて競争状況と市場ポジショニングの分析。

四.本腫瘍薬のレポートでは関係者が市場の競争状況を包括的に理解し、事業戦略や市場戦略を的確に立てるのに役立つ洞察を提供することを目的としています。 売上高、成長動向、生産技術、用途、エンドユーザー産業の市場規模に関する詳細な評価と予測を提供し、意思決定者に強力なデータサポートを提供します。

章の概要
第1章：腫瘍薬のレポート範囲、各市場セグメントの市場規模、将来の開発可能性などを含む、さまざまな市場セグメントのエグゼクティブサマリー（タイプ別およびアプリケーション別など）を紹介します。市場の現状と、短期から中期、および長期的な進化の可能性を高度に見ることができます。（2020～2031）
第2章： 腫瘍薬の世界と主要生産者（地域／国）の生産／アウトプット。各生産者の生産量と今後6年間の発展可能性を定量的に分析しています。（2020～2031）
第3章：世界、地域、国レベルにおける腫瘍薬の売上（消費）、収益。各地域とその主要国の市場規模と発展の可能性を定量的に分析し、世界の各国の市場発展、将来の発展の見通し、市場空間を紹介します。（2020～2031）
第4章腫瘍薬メーカーの競争状況、価格、売上高、収益、市場シェアと業界ランキング、最新の開発計画、合併、買収情報などの詳細分析。（2020～2025）
第5章：腫瘍薬の各市場セグメントの売上高、収益、平均価格、および開発可能性をカバーした種類別のさまざまな市場セグメントの分析を提供し、読者がさまざまな市場セグメントでブルーオーシャン市場を見つけるのに役立ちます。（2020～2031）
第6章：アプリケーション別の様々な市場セグメントの分析を提供し、各市場セグメントの売上高、収益、平均価格、発展の可能性をカバーし、読者が異なる下流市場でのブルーオーシャン市場を見つけるのに役立ちます。（2020～2031）
第7章：北米（米国・カナダ）：タイプ別、用途別、国別、セグメント別の売上高、収益。（2020～2031）
第8章：ヨーロッパ：タイプ別、用途別、国別、セグメント別の売上高と収益。（2020～2031）
第9章：中国：タイプ別、アプリケーション別、セグメント別の売上高、収益。（2020～2031）
第10章：アジア（中国を除く）：タイプ別、用途別、地域別、セグメント別の売上高、収益。（2020～2031）
第11章：中東、アフリカ、中南米：タイプ別、用途別、国別、セグメント別の売上高、収益。（2020～2031）
第12章：腫瘍薬の主要メーカーの概要を提供し、製品の説明と仕様、腫瘍薬の売上高、収益、価格、粗利益率、最近の発展など、市場の主要企業の基本的な状況を詳細に紹介します。（2020～2025）
第13章：産業チェーン、販売チャネル、主要原材料、販売代理店および顧客の分析。
第14章：腫瘍薬の市場動態、市場の最新の動向、市場の推進要因と制約要因、業界内のメーカーが直面する課題とリスク、業界内の関連政策の分析を紹介します。
第15章：レポートの要点と結論。

The global Oncology Drugs market is projected to grow from US$ 262090 million in 2025 to US$ 446860 million by 2031, at a Compound Annual Growth Rate (CAGR) of 9.3% during the forecast period.
Oncology drugs are pharmaceutical agents used to prevent, treat, or manage various types of cancer. This category includes chemotherapy, targeted therapies, immunotherapies, hormone therapies, and emerging treatments such as cell-based therapies like CAR-T. These drugs function through different mechanisms, such as inhibiting cancer cell growth, inducing apoptosis, blocking angiogenesis, or enhancing the immune system’s ability to recognize and destroy malignant cells. Oncology drugs play a critical role in modern medicine and represent one of the most dynamic and innovative sectors in the pharmaceutical industry.
The oncology drugs market is experiencing robust growth driven by the increasing global burden of cancer and rising awareness of early diagnosis and treatment. Aging populations, lifestyle-related risk factors such as smoking, poor diet, and lack of physical activity, along with environmental exposures, have all contributed to higher cancer incidence rates. Technological advancements in molecular biology and genomics have accelerated the development of targeted therapies, immunotherapies, and personalized medicine, which offer improved efficacy with fewer side effects. Governments and health organizations worldwide are increasing investments in cancer research, diagnostics, and treatment infrastructure, further supporting market expansion. Additionally, the growing adoption of biosimilars and the introduction of new drug classes like CAR-T cell therapies and checkpoint inhibitors are enhancing treatment options and accessibility for patients across various cancer types.
Despite significant progress, the oncology drugs market faces notable challenges. One of the key issues is the high cost of cancer drugs, particularly biologics and targeted therapies, which poses a financial burden on healthcare systems and patients, especially in low- and middle-income countries. Drug development in oncology is highly complex, expensive, and time-consuming, with a high failure rate during clinical trials. Regulatory hurdles, including long approval timelines and stringent safety requirements, can delay the introduction of innovative therapies. Moreover, the emergence of drug resistance in certain cancers, such as melanoma or non-small cell lung cancer, limits the long-term effectiveness of current treatments. Inequitable access to oncology care, due to disparities in healthcare infrastructure, insurance coverage, and geographical availability, further restricts market reach and poses a major public health concern globally.
In terms of production side, this report researches the Oncology Drugs production, growth rate, market share by manufacturers and by region (region level and country level), from 2020 to 2025, and forecast to 2031.

In terms of consumption side, this report focuses on the sales of Oncology Drugs by region (region level and country level), by company, by Type and by Application. from 2020 to 2025 and forecast to 2031.
This report presents an overview of global market for Oncology Drugs, capacity, output, revenue and price. Analyses of the global market trends, with historic market revenue/sales data for 2020 - 2025, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Oncology Drugs, also provides the consumption of main regions and countries. Highlights of the upcoming market potential for Oncology Drugs, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Oncology Drugs sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Oncology Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way. 
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Oncology Drugs sales, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Roche, Celgene, Novartis, Bristol-Myers Squibb, Johnson & Johnson, Merck & Co., AstraZeneca, Pfizer, Amgen, Eli Lilly, etc.
Market Segmentation
By Company
    Roche
    Celgene
    Novartis
    Bristol-Myers Squibb
    Johnson & Johnson
    Merck & Co.
    AstraZeneca
    Pfizer
    Amgen
    Eli Lilly
    AbbVie
    Takeda
    Astellas
    Ipsen
    Sanofi
    Bayer
    Biogen Idec
    Teva
    Otsuka
    Eisai
    Merck KGaA
    Gilead Sciences
    Hengrui Medicine

Segment by Type
    Chemotherapy
    Targeted Therapy
    Immunotherapy (Biologic Therapy)
    Hormonal Therapy
    Others

Segment by Application
    Blood Cancer
    Breast Cancer
    Gastrointestinal Cancer
    Prostate Cancer
    Respiratory or Lung Cancer
    Others

Production by Region
    North America
    Europe
    Israel
    Japan
    China

Sales by Region
    US & Canada
        U.S.
        Canada
    China
    Asia (excluding China)
        Japan
        South Korea
        China Taiwan
        Southeast Asia
    Europe
        Germany
        France
        U.K.
        Italy
        Russia

Middle East, Africa, Latin America
        Brazil
        Mexico
        Turkey
        Israel

Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type and by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Oncology Drugs production/output of global and key producers (regions/countries). It provides a quantitative analysis of the production, and development potential of each producer in the next six years.
Chapter 3: Sales (consumption), revenue of Oncology Drugs in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 4: Detailed analysis of Oncology Drugs manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by Type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by Application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: North America (US & Canada) by Type, by Application and by country, sales, and revenue for each segment.
Chapter 8: Europe by Type, by Application and by country, sales, and revenue for each segment.
Chapter 9: China by Type, and by Application, sales, and revenue for each segment.
Chapter 10: Asia (excluding China) by Type, by Application and by region, sales, and revenue for each segment.
Chapter 11: Middle East, Africa, Latin America by Type, by Application and by country, sales, and revenue for each segment.
Chapter 12: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Oncology Drugs sales, revenue, price, gross margin, and recent development, etc.
Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 14: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 15: The main points and conclusions of the report.

List of Tables
 Table 1. Global Oncology Drugs Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
 Table 2. Key Players of Chemotherapy
 Table 3. Key Players of Targeted Therapy
 Table 4. Key Players of Immunotherapy (Biologic Therapy)
 Table 5. Key Players of Hormonal Therapy
 Table 6. Key Players of Others
 Table 7. Global Oncology Drugs Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
 Table 8. Global Oncology Drugs Market Size Growth Rate (CAGR) by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 9. Global Market Size by Region (2020-2031) & (US$ Million)
 Table 10. Global Oncology Drugs Market Share by Region (2020-2031)
 Table 11. Market Trends
 Table 12. Market Drivers
 Table 13. Market Challenges
 Table 14. Market Restraints
 Table 15. Global Oncology Drugs Revenue by Players (2020-2025) & (US$ Million)
 Table 16. Global Oncology Drugs Market Share by Players (2020-2025)
 Table 17. Global Top Oncology Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oncology Drugs as of 2024)
 Table 18. Global Oncology Drugs Industry Ranking 2023 VS 2024
 Table 19. Global 5 Largest Players Market Share by Oncology Drugs Revenue (CR5 and HHI) & (2020-2025)
 Table 20. Global Key Players of Oncology Drugs, Headquarters and Area Served
 Table 21. Global Key Players of Oncology Drugs, Product and Application
 Table 22. Global Key Players of Oncology Drugs, Date of Enter into This Industry
 Table 23. Mergers & Acquisitions, Expansion Plans
 Table 24. Global Market Size by Type (2020-2025) & (US$ Million)
 Table 25. Global Oncology Drugs Revenue Market Share by Type (2020-2025)
 Table 26. Global Forecasted Market Size by Type (2026-2031) & (US$ Million)
 Table 27. Global Oncology Drugs Revenue Market Share by Type (2026-2031)
 Table 28. Global Market Size by Application (2020-2025) & (US$ Million)
 Table 29. Global Oncology Drugs Revenue Market Share by Application (2020-2025)
 Table 30. Global Forecasted Market Size by Application (2026-2031) & (US$ Million)
 Table 31. Global Oncology Drugs Revenue Market Share by Application (2026-2031)
 Table 32. North America Market Size by Type (2020-2031) & (US$ Million)
 Table 33. North America Market Size by Application (2020-2031) & (US$ Million)
 Table 34. North America Oncology Drugs Growth Rate (CAGR) by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 35. North America Market Size by Country (2020-2031) & (US$ Million)
 Table 36. Europe Market Size by Type (2020-2031) & (US$ Million)
 Table 37. Europe Market Size by Application (2020-2031) & (US$ Million)
 Table 38. Europe Oncology Drugs Growth Rate (CAGR) by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 39. Europe Market Size by Country (2020-2025) & (US$ Million)
 Table 40. China Market Size by Type (2020-2031) & (US$ Million)
 Table 41. China Market Size by Application (2020-2031) & (US$ Million)
 Table 42. Asia Market Size by Type (2020-2031) & (US$ Million)
 Table 43. Asia Market Size by Application (2020-2025) & (US$ Million)
 Table 44. Asia Oncology Drugs Growth Rate (CAGR) by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 45. Asia Market Size by Region (2020-2031) & (US$ Million)
 Table 46. Middle East, Africa, and Latin America Market Size by Type (2020-2031) & (US$ Million)
 Table 47. Middle East, Africa, and Latin America Market Size by Application (2020-2031) & (US$ Million)
 Table 48. Middle East, Africa, and Latin America Oncology Drugs Growth Rate (CAGR) by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 49. Middle East, Africa, and Latin America Market Size by Country (2020-2031) & (US$ Million)
 Table 50. Roche Company Details
 Table 51. Roche Business Overview
 Table 52. Roche Oncology Drugs Product
 Table 53. Roche Revenue (2020-2025) & (US$ Million)
 Table 54. Roche Recent Development
 Table 55. Celgene Company Details
 Table 56. Celgene Business Overview
 Table 57. Celgene Oncology Drugs Product
 Table 58. Celgene Revenue (2020-2025) & (US$ Million)
 Table 59. Celgene Recent Development
 Table 60. Novartis Company Details
 Table 61. Novartis Business Overview
 Table 62. Novartis Oncology Drugs Product
 Table 63. Novartis Revenue (2020-2025) & (US$ Million)
 Table 64. Novartis Recent Development
 Table 65. Bristol-Myers Squibb Company Details
 Table 66. Bristol-Myers Squibb Business Overview
 Table 67. Bristol-Myers Squibb Oncology Drugs Product
 Table 68. Bristol-Myers Squibb Revenue (2020-2025) & (US$ Million)
 Table 69. Bristol-Myers Squibb Recent Development
 Table 70. Johnson & Johnson Company Details
 Table 71. Johnson & Johnson Business Overview
 Table 72. Johnson & Johnson Oncology Drugs Product
 Table 73. Johnson & Johnson Revenue (2020-2025) & (US$ Million)
 Table 74. Johnson & Johnson Recent Development
 Table 75. Merck & Co. Company Details
 Table 76. Merck & Co. Business Overview
 Table 77. Merck & Co. Oncology Drugs Product
 Table 78. Merck & Co. Revenue (2020-2025) & (US$ Million)
 Table 79. Merck & Co. Recent Development
 Table 80. AstraZeneca Company Details
 Table 81. AstraZeneca Business Overview
 Table 82. AstraZeneca Oncology Drugs Product
 Table 83. AstraZeneca Revenue (2020-2025) & (US$ Million)
 Table 84. AstraZeneca Recent Development
 Table 85. Pfizer Company Details
 Table 86. Pfizer Business Overview
 Table 87. Pfizer Oncology Drugs Product
 Table 88. Pfizer Revenue (2020-2025) & (US$ Million)
 Table 89. Pfizer Recent Development
 Table 90. Amgen Company Details
 Table 91. Amgen Business Overview
 Table 92. Amgen Oncology Drugs Product
 Table 93. Amgen Revenue (2020-2025) & (US$ Million)
 Table 94. Amgen Recent Development
 Table 95. Eli Lilly Company Details
 Table 96. Eli Lilly Business Overview
 Table 97. Eli Lilly Oncology Drugs Product
 Table 98. Eli Lilly Revenue (2020-2025) & (US$ Million)
 Table 99. Eli Lilly Recent Development
 Table 100. AbbVie Company Details
 Table 101. AbbVie Business Overview
 Table 102. AbbVie Oncology Drugs Product
 Table 103. AbbVie Revenue (2020-2025) & (US$ Million)
 Table 104. AbbVie Recent Development
 Table 105. Takeda Company Details
 Table 106. Takeda Business Overview
 Table 107. Takeda Oncology Drugs Product
 Table 108. Takeda Revenue (2020-2025) & (US$ Million)
 Table 109. Takeda Recent Development
 Table 110. Astellas Company Details
 Table 111. Astellas Business Overview
 Table 112. Astellas Oncology Drugs Product
 Table 113. Astellas Revenue (2020-2025) & (US$ Million)
 Table 114. Astellas Recent Development
 Table 115. Ipsen Company Details
 Table 116. Ipsen Business Overview
 Table 117. Ipsen Oncology Drugs Product
 Table 118. Ipsen Revenue (2020-2025) & (US$ Million)
 Table 119. Ipsen Recent Development
 Table 120. Sanofi Company Details
 Table 121. Sanofi Business Overview
 Table 122. Sanofi Oncology Drugs Product
 Table 123. Sanofi Revenue (2020-2025) & (US$ Million)
 Table 124. Sanofi Recent Development
 Table 125. Bayer Company Details
 Table 126. Bayer Business Overview
 Table 127. Bayer Oncology Drugs Product
 Table 128. Bayer Revenue (2020-2025) & (US$ Million)
 Table 129. Bayer Recent Development
 Table 130. Biogen Idec Company Details
 Table 131. Biogen Idec Business Overview
 Table 132. Biogen Idec Oncology Drugs Product
 Table 133. Biogen Idec Revenue (2020-2025) & (US$ Million)
 Table 134. Biogen Idec Recent Development
 Table 135. Teva Company Details
 Table 136. Teva Business Overview
 Table 137. Teva Oncology Drugs Product
 Table 138. Teva Revenue (2020-2025) & (US$ Million)
 Table 139. Teva Recent Development
 Table 140. Otsuka Company Details
 Table 141. Otsuka Business Overview
 Table 142. Otsuka Oncology Drugs Product
 Table 143. Otsuka Revenue (2020-2025) & (US$ Million)
 Table 144. Otsuka Recent Development
 Table 145. Eisai Company Details
 Table 146. Eisai Business Overview
 Table 147. Eisai Oncology Drugs Product
 Table 148. Eisai Revenue (2020-2025) & (US$ Million)
 Table 149. Eisai Recent Development
 Table 150. Merck KGaA Company Details
 Table 151. Merck KGaA Business Overview
 Table 152. Merck KGaA Oncology Drugs Product
 Table 153. Merck KGaA Revenue (2020-2025) & (US$ Million)
 Table 154. Merck KGaA Recent Development
 Table 155. Gilead Sciences Company Details
 Table 156. Gilead Sciences Business Overview
 Table 157. Gilead Sciences Oncology Drugs Product
 Table 158. Gilead Sciences Revenue (2020-2025) & (US$ Million)
 Table 159. Gilead Sciences Recent Development
 Table 160. Hengrui Medicine Company Details
 Table 161. Hengrui Medicine Business Overview
 Table 162. Hengrui Medicine Oncology Drugs Product
 Table 163. Hengrui Medicine Revenue (2020-2025) & (US$ Million)
 Table 164. Hengrui Medicine Recent Development
 Table 165. Research Programs/Design for This Report
 Table 166. Key Data Information from Secondary Sources
 Table 167. Key Data Information from Primary Sources


List of Figures
 Figure 1. Global Oncology Drugs Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 2. Global Oncology Drugs Market Share by Type: 2024 VS 2031
 Figure 3. Chemotherapy Features
 Figure 4. Targeted Therapy Features
 Figure 5. Immunotherapy (Biologic Therapy) Features
 Figure 6. Hormonal Therapy Features
 Figure 7. Others Features
 Figure 8. Global Oncology Drugs Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 9. Global Oncology Drugs Market Share by Application: 2024 VS 2031
 Figure 10. Blood Cancer Case Studies
 Figure 11. Breast Cancer Case Studies
 Figure 12. Gastrointestinal Cancer Case Studies
 Figure 13. Prostate Cancer Case Studies
 Figure 14. Respiratory or Lung Cancer Case Studies
 Figure 15. Others Case Studies
 Figure 16. Oncology Drugs Report Years Considered
 Figure 17. Global Oncology Drugs Market Size (US$ Million), Year-over-Year: 2020-2031
 Figure 18. Global Oncology Drugs Market Size, (US$ Million), 2020 VS 2024 VS 2031
 Figure 19. Global Oncology Drugs Market Share by Region: 2024 VS 2031
 Figure 20. Global Oncology Drugs Market Share by Players in 2024
 Figure 21. Global Top Oncology Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oncology Drugs as of 2024)
 Figure 22. The Top 10 and 5 Players Market Share by Oncology Drugs Revenue in 2024
 Figure 23. North America Oncology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 24. North America Oncology Drugs Market Share by Type (2020-2031)
 Figure 25. North America Oncology Drugs Market Share by Application (2020-2031)
 Figure 26. North America Oncology Drugs Market Share by Country (2020-2031)
 Figure 27. United States Oncology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 28. Canada Oncology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 29. Europe Oncology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 30. Europe Oncology Drugs Market Share by Type (2020-2031)
 Figure 31. Europe Oncology Drugs Market Share by Application (2020-2031)
 Figure 32. Europe Oncology Drugs Market Share by Country (2020-2031)
 Figure 33. Germany Oncology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 34. France Oncology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 35. U.K. Oncology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 36. Italy Oncology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 37. Russia Oncology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 38. Nordic Countries Oncology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 39. China Oncology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 40. China Oncology Drugs Market Share by Type (2020-2031)
 Figure 41. China Oncology Drugs Market Share by Application (2020-2031)
 Figure 42. Asia Oncology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 43. Asia Oncology Drugs Market Share by Type (2020-2031)
 Figure 44. Asia Oncology Drugs Market Share by Application (2020-2031)
 Figure 45. Asia Oncology Drugs Market Share by Region (2020-2031)
 Figure 46. Japan Oncology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 47. South Korea Oncology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 48. China Taiwan Oncology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 49. Southeast Asia Oncology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 50. India Oncology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 51. Australia Oncology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 52. Middle East, Africa, and Latin America Oncology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 53. Middle East, Africa, and Latin America Oncology Drugs Market Share by Type (2020-2031)
 Figure 54. Middle East, Africa, and Latin America Oncology Drugs Market Share by Application (2020-2031)
 Figure 55. Middle East, Africa, and Latin America Oncology Drugs Market Share by Country (2020-2031)
 Figure 56. Brazil Oncology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 57. Mexico Oncology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 58. Turkey Oncology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 59. Saudi Arabia Oncology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 60. Israel Oncology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 61. GCC Countries Oncology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 62. Roche Revenue Growth Rate in Oncology Drugs Business (2020-2025)
 Figure 63. Celgene Revenue Growth Rate in Oncology Drugs Business (2020-2025)
 Figure 64. Novartis Revenue Growth Rate in Oncology Drugs Business (2020-2025)
 Figure 65. Bristol-Myers Squibb Revenue Growth Rate in Oncology Drugs Business (2020-2025)
 Figure 66. Johnson & Johnson Revenue Growth Rate in Oncology Drugs Business (2020-2025)
 Figure 67. Merck & Co. Revenue Growth Rate in Oncology Drugs Business (2020-2025)
 Figure 68. AstraZeneca Revenue Growth Rate in Oncology Drugs Business (2020-2025)
 Figure 69. Pfizer Revenue Growth Rate in Oncology Drugs Business (2020-2025)
 Figure 70. Amgen Revenue Growth Rate in Oncology Drugs Business (2020-2025)
 Figure 71. Eli Lilly Revenue Growth Rate in Oncology Drugs Business (2020-2025)
 Figure 72. AbbVie Revenue Growth Rate in Oncology Drugs Business (2020-2025)
 Figure 73. Takeda Revenue Growth Rate in Oncology Drugs Business (2020-2025)
 Figure 74. Astellas Revenue Growth Rate in Oncology Drugs Business (2020-2025)
 Figure 75. Ipsen Revenue Growth Rate in Oncology Drugs Business (2020-2025)
 Figure 76. Sanofi Revenue Growth Rate in Oncology Drugs Business (2020-2025)
 Figure 77. Bayer Revenue Growth Rate in Oncology Drugs Business (2020-2025)
 Figure 78. Biogen Idec Revenue Growth Rate in Oncology Drugs Business (2020-2025)
 Figure 79. Teva Revenue Growth Rate in Oncology Drugs Business (2020-2025)
 Figure 80. Otsuka Revenue Growth Rate in Oncology Drugs Business (2020-2025)
 Figure 81. Eisai Revenue Growth Rate in Oncology Drugs Business (2020-2025)
 Figure 82. Merck KGaA Revenue Growth Rate in Oncology Drugs Business (2020-2025)
 Figure 83. Gilead Sciences Revenue Growth Rate in Oncology Drugs Business (2020-2025)
 Figure 84. Hengrui Medicine Revenue Growth Rate in Oncology Drugs Business (2020-2025)
 Figure 85. Bottom-up and Top-down Approaches for This Report
 Figure 86. Data Triangulation
 Figure 87. Key Executives Interviewed